POTS Article 2: Treatments for POTS and Dysautonomia in ME/CFS — Salt, Fludrocortisone, Midodrine, Ivabradine, and What It Means When They Don’t Work
If you have ME/CFS and POTS — or even just the racing-heart-and-dizzy-on-standing symptoms — the first thing you are told is to eat more salt. After that, the drugs come with names you have never heard: fludrocortisone, midodrine, ivabradine.
This article explains the medications themselves: what each does, where the evidence stands, the honest limits, and — the part people ask about most — what it means when they do not work.
For the conceptual background — what POTS is, why the blood volume is low but the hormone that fixes it is paradoxically off, and the difference between POTS-alone and ME/CFS-with-POTS — see the companion overview article.
1 First, a plain warning
Everything below is a medicine you will likely be offered, not self-medication advice. These drugs change your heart rate, your blood pressure, and your blood volume — they are not harmless, and in ME/CFS the wrong drug or the wrong dose can set you back. Talk to a prescriber before starting, stopping, or changing any of them. If your symptoms feel sudden, severe, or life-threatening — especially chest pain, loss of consciousness, or any symptom that feels like a heart attack — that is an emergency. Go to a hospital.
2 The treatment ladder, in order
POTS treatment runs from the simplest and safest to the most pharmacology-heavy. Not every step applies, and not every drug is right for every person — but the logic is the same: start with what the body already needs and cannot regulate (volume, salt, compression), then add drugs that restore specific failures in the system.
2.1 Step one: volume, salt, compression — the foundation
These are the lowest-risk interventions and, for many people, the most effective.
Blood volume expansion. Because the renin-aldosterone system is paradoxically suppressed — your body is not holding onto salt and water the way it should — the first, simplest intervention is to give it more to work with. This usually means:
- Increased fluid intake (2–3 litres per day, adjusted to body size and climate).
- Increased dietary sodium (a typical target is 3–6 g of added sodium per day — toward the high end only under explicit prescriber guidance; briefly higher in the acute phase is possible but not a standing target). One caution: high sodium impairs endothelial function and increases left ventricular mass independent of blood pressure, so the dose needs to be monitored rather than maximised (Stock et al. 2022). A prescriber should check blood pressure and monitor urinary sodium during high-salt protocols.
- Compression stockings. A controlled study in ME/CFS found that waist-high compression stockings (20–30 mmHg) improved cardiac output and cerebral blood flow during tilt testing (Visser, Campen, and Rowe 2022). Abdominal compression may matter more than leg compression, because the splanchnic bed holds a large fraction of pooled blood. Thigh-high or knee-high alone is often insufficient; the full garment to the waist is more effective.
The honest limit. These interventions are safe, cheap, and evidence-supported for orthostatic intolerance — but in severe ME/CFS, the physical effort of drinking, preparing salt-rich food, and pulling on compression garments can itself trigger PEM. A caregiver’s help with the compression garment can make the difference between a useful intervention and a harmful one.
2.2 Step two: fludrocortisone — the volume hormone your body is not making
Fludrocortisone is a synthetic mineralocorticoid. It mimics aldosterone — the hormone that tells your kidneys to hold onto sodium and water. In POTS and ME/CFS, aldosterone is paradoxically low despite low blood volume [Raj et al. (2005)](Miwa and Fujita 2017). Fludrocortisone works by filling that gap: it expands plasma volume over days to weeks.
What the evidence says. A 2000 study of bisoprolol (a beta-blocker) plus fludrocortisone in orthostatic intolerance found the combination more effective than either drug alone (Freitas et al. 2000). The pediatric POTS literature reports high response rates, though these come from uncontrolled studies and the placebo response in POTS is substantial (Ojha, McNeeley, et al. 2024). A systematic review of oral POTS medications confirmed fludrocortisone as a widely used first-line agent, though the evidence base remains largely observational (Pierson et al. 2025).
Practical considerations. Fludrocortisone takes weeks to show its full effect, because plasma volume expansion is slow. It can cause hypokalemia (low potassium), so potassium levels need monitoring. It can raise blood pressure and cause headaches. The dose is typically 0.05–0.2 mg daily, started low and titrated. At these doses it works as a mineralocorticoid — it signals the kidneys to hold sodium and water, and it blunts the body’s own renin–angiotensin–aldosterone system. It is not a drug to stop abruptly, and stopping should be tapered under supervision rather than stopping cold.
2.3 Step three: midodrine — tightening the vessels
Midodrine is an α₁-adrenergic agonist — it tells the smooth muscle in blood vessels to constrict. It works within an hour and lasts about four hours, so it is timed around upright activity (morning, before showers, before standing tasks). It does not cross the blood-brain barrier much, so it raises peripheral resistance without major central-nervous-system effects.
What the evidence says. A 2026 systematic review and meta-analysis (14 studies, 968 patients) found midodrine increased symptom response in pediatric POTS (relative risk 1.52, p=0.01), but the evidence in adults is limited and the studies were mostly uncontrolled (Kwok et al. 2026). Hypertension occurred in 8.2% of patients — a real risk, and the reason supine blood pressure must be monitored. Midodrine should not be taken within four hours of lying down, because supine hypertension is the drug’s main danger. In practice, this means timing doses around upright activity and checking blood pressure lying and standing.
Practical considerations. Midodrine is a short-acting drug with a clear on-off profile. A common dosing pattern is 2.5–10 mg, 3–4 times daily, with the last dose no later than early evening to avoid supine hypertension overnight. Scalp tingling (piloerection) is a common side effect — it is unpleasant but not dangerous, and it signals the drug is active. Urinary retention can occur. In ME/CFS, where physical activity is already severely limited, the practical benefit — being able to stand for a shower or prepare food — can outweigh the inconvenience, but only if the drug does not worsen PEM through the activity it enables.
2.4 Step four: ivabradine and beta-blockers — slowing the rate without dropping pressure
If volume expansion and vasoconstriction are not enough, the next step targets the heart rate directly — but the choice of drug matters a great deal in ME/CFS.
Ivabradine is a relatively new drug that slows the heart rate by blocking the funny channel (I_f) in the sinoatrial node — the heart’s natural pacemaker. Unlike beta-blockers, it does not lower blood pressure significantly, causes little or no bronchospasm, and its fatigue effect is generally lighter than a beta-blocker’s — though fatigue and headache are still possible, so it is not literally “fatigue-free” and should not be sold that way in an ME/CFS population. It is an attractive option in POTS because the problem is tachycardia without hypotension — slowing the rate without dropping the pressure further (Marchetta et al. 2025). The usual dose is 2.5–5 mg twice daily, taken with food, and it can cause visual brightness phenomena (phosphenes) and, occasionally, bradycardia requiring a reduced dose, so a slow upward titration with heart-rate monitoring is sensible. Two practical cautions that matter in this series specifically: ivabradine is a CYP3A4 substrate, so it is contraindicated with strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) and should be used cautiously with the azole antifungals and other potent CYP3A4 modulators — and combining it with a beta-blocker adds bradycardia risk; and ivabradine is off-label for POTS in most settings, often expensive, and subject to prior authorisation or denial, so access is an obstacle for many patients. The honest limitation: ivabradine effectively reduces heart rate in POTS but symptom improvement is inconsistent — the 2025 systematic review of oral POTS treatments found that while ivabradine lowers the number, the correlation between heart-rate reduction and symptom relief is weak (Pierson et al. 2025).
Beta-blockers (propranolol, bisoprolol, metoprolol) block the β-adrenergic receptors that mediate sympathetic stimulation of the heart. Low-dose propranolol (10–20 mg) can blunt the standing heart-rate spike without dropping blood pressure, but beta-blockers are associated with fatigue, exercise intolerance, and — in some people — worsened brain fog. In ME/CFS, where fatigue is already the central complaint, a drug that adds fatigue is a serious trade-off. Bisoprolol (a β₁-selective blocker, typically started at 1.25–2.5 mg daily) plus fludrocortisone has the best evidence for combination therapy in orthostatic intolerance (Freitas et al. 2000). The practical rule: start with a low dose of a cardioselective beta-blocker and watch for worsened fatigue — if it appears, stop and consider ivabradine or a non-pharmacological approach instead.
2.5 Step five: pyridostigmine — the acetylcholine booster
Pyridostigmine is a peripheral acetylcholinesterase inhibitor — it increases acetylcholine at the synapses of the parasympathetic nervous system. In POTS, the rationale is that boosting parasympathetic tone will reduce the standing heart-rate spike, particularly in the neuropathic subtype where sympathetic signalling is intact but the parasympathetic brake is weak. A 2025 systematic review and meta-analysis found pyridostigmine reduced the orthostatic blood-pressure drop, but alone the effect did not reach statistical significance — it was significant only when combined with midodrine; a factorial RCT (the LIFT trial, pyridostigmine + low-dose naltrexone in ME/CFS) is currently underway [Pavic et al. (2025)](Meadows et al. 2025).
Practical considerations. Pyridostigmine is generally well tolerated, with gastrointestinal side effects (cramping, diarrhoea) as the main limitation. It is taken 30–60 mg, 2–3 times daily. In ME/CFS, the GI side effects can be a problem in patients who already have gut dysmotility or irritable-bowel symptoms, so starting low (30 mg once daily) is safer.
2.6 A word on what not to take: the SSRI pitfall
Selective serotonin reuptake inhibitors (SSRIs — fluoxetine, sertraline, escitalopram) are sometimes prescribed for POTS on the assumption that they stabilise autonomic function. A 2014 randomized crossover trial of acute sertraline in POTS found the opposite: SSRIs increased standing heart rate and worsened symptoms (Mar et al. 2014). This is consistent with a broader finding that POTS is associated with platelet serotonin storage-pool deficiency — 81% of POTS patients in one study had measurable platelet delta-granule deficiency, and platelet serotonin concentrations were significantly lower than controls (Gunning et al. 2016). A drug that blocks serotonin reuptake may be pushing the wrong neurotransmitter in the wrong direction for this population. In ME/CFS, where SSRIs already have a weak evidence base for the core fatigue and PEM, the additional risk of worsening orthostatic symptoms makes them a poor choice unless there is a clear, independent indication.
3 Expected results
Be realistic, and be patient. POTS treatment in ME/CFS is a trial, not a guarantee.
- Volume and salt work for many, but not all — and not forever. The renin-aldosterone paradox means the body is not holding volume adequately on its own, so volume expansion often helps — but a subset of patients are volume-resistant for reasons that are not yet understood.
- A drug trial takes weeks, not days. Fludrocortisone takes weeks to expand plasma volume. Midodrine works within an hour but the dosing schedule needs adjustment. Ivabradine reduces heart rate immediately, but the symptom benefit (if it comes) may lag.
- Partial response is the most common outcome. You might stand longer with midodrine, shower with less dizziness with compression, and still have the fatigue. That is not a failure — it is a partial win in a multi-input problem.
- The POTS-dominant subgroup may respond better. In the large Eckey et al. treatment survey, autonomic modulators helped the POTS-dominant cluster regardless of originating diagnosis, and the cluster membership — not the ME/CFS-versus-Long-COVID label — was the strongest predictor (Eckey et al. 2025). If your orthostatic symptoms are prominent, POTS treatment is more likely to give a meaningful return.
- Prescriber coordination matters. If you are also on antihistamines for MCAS, the blood-pressure and sedation effects of up-dosed H1 antihistamines and the potential cimetidine drug-drug interactions need to be assessed together with POTS medications. This is a case for one clinician holding the full medication list.
4 An example “structured trial”
This is an example to give your clinician something to work from — not a self-prescription. The prescriber chooses the drug, dose, and duration.
A practical frame: pick one target symptom (e.g., standing time before dizziness, or tolerance for a shower). Start with the foundation — salt, water, compression — and assess at 4 weeks. If there is no improvement, start fludrocortisone at 0.05 mg daily and reassess at 6 weeks. Only after reaching a tolerated dose (typically 0.1–0.2 mg, blood pressure and potassium permitting) is the drug judged. If fludrocortisone fails at an adequate dose and duration, add or switch to midodrine (2.5–10 mg timed before upright activity), reassess at 4 weeks, with a supine-BP safety gate. If midodrine fails, consider ivabradine or a low-dose cardioselective beta-blocker. Only add a second drug once the first has been judged at an adequate dose and duration — polypharmacy before monotherapy evaluation makes it impossible to know what helped.
Coordinate across conditions. If you are also on antihistamines for MCAS, the blood-pressure and sedation effects of up-dosed H1 antihistamines and the potential cimetidine drug-drug interactions need to be assessed together with POTS medications. Famotidine is the safer H2 default over cimetidine, which is a potent CYP450 inhibitor (Loth 2026). One clinician should hold the full medication list.
5 What it means if the treatment does not work
This is the honest section. A failed POTS drug trial is common, and it means several specific things — none of which is a verdict on whether your illness is real.
One: it may not have been the right drug or the right dose. POTS has multiple mechanisms — low volume, low aldosterone, venous pooling, mast-cell vasodilation, endothelial dysfunction, autoantibodies, connective-tissue laxity — and a single drug addresses only one. If fludrocortisone fails, it could mean your volume deficit is not aldosterone-responsive (e.g., if the problem is venous pooling, not low volume). If midodrine fails, it could mean vasoconstriction is not the limiting factor. A single failed drug does not test the whole system — it tests one mechanism.
Two: poor diagnostic specificity of the POTS label itself means some failures are misclassification. The 30-bpm threshold catches healthy controls, misses people with severe orthostatic symptoms who do not cross it, and has poor day-to-day reproducibility (ME/CFS Science 2024). If your POTS diagnosis was based on a single borderline test, and the drug fails, one honest possibility is that the orthostatic intolerance is real but the “POTS” label was not a good fit for the underlying mechanism — and a broader dysautonomia frame (treating cerebral hypoperfusion, not just the heart-rate number) may be a better target.
Three: the renin-aldosterone paradox may be drug-resistant in a subset. If the volume-regulating thermostat is set wrong at a central-nervous-system level — and there is evidence of brainstem dysfunction in ME/CFS, including white-matter volume decreases in the midbrain that correlate with disease duration (Barnden et al. 2011) — then peripheral drugs that try to override that central signal (like fludrocortisone) may be only partially effective.
Four: mast-cell and connective-tissue inputs may dominate. If venous pooling from hypermobility is the main driver, vasoconstriction and volume expansion may help less than compression and postural strategies. If mast-cell mediators are dilating vessels, the heart rate is a downstream sign and the upstream target is mast-cell stabilisation — covered in the MCAS overview in this series.
Five: the treatment may be working on the heart but missing the brain. The cerebral blood flow data in ME/CFS shows that abnormal brain perfusion occurs even with normal heart rate and blood pressure [Campen et al. (2020)](Campen et al. 2024). A drug that normalises heart rate without improving cerebral blood flow will not fix the dizziness and brain fog. The honest limit: we do not yet have a drug that directly targets endothelial function or cerebral autoregulation in ME/CFS. Compression stockings and volume expansion are the closest we have, and they are mechanical, not pharmacological.
Six — the honest core: A single failed POTS drug trial does not disprove dysautonomia, because the drug tests one mechanism in a multi-mechanism system. A sequence of well-run trials across drug classes — volume expansion, vasoconstriction, rate control — that produce no benefit genuinely lowers the probability that the autonomic system is the dominant amplifier, and that is useful information. Either way, no POTS treatment result disproves ME/CFS, which is far larger than any one pathway. Distinguish the two claims: “one drug failed” is a clue about one mechanism; “your illness is not real” is never a valid conclusion from a drug trial.
6 The falsifiable predictions
For those who find the framework useful, here is what would confirm or refute the POTS-in-ME/CFS story:
- If supine norepinephrine is elevated and heart rate normalises with α-blockade, peripheral sympathetic excess is confirmed as a contributor — a falsifiable, individually testable prediction (Loth 2026).
- If volume expansion (salt + fludrocortisone) reduces orthostatic heart rate but does not improve cerebral blood flow or core fatigue, that supports orthostatic intolerance being a contributor to some features while the energy failure and endothelial dysfunction are elsewhere.
- If ivabradine reduces heart rate to normal but cognitive symptoms and PEM are unchanged, that supports the cerebral-hypoperfusion data — the heart rate is a sign, not the lesion — and points toward endothelial or autoregulatory targets.
- If mast-cell stabilisers (cromolyn, ketotifen) reduce orthostatic symptoms in the MCAS-positive subset, that supports mast-cell mediators being a vascular amplifier — with the caveat that an uncontrolled individual response cannot disentangle placebo from mechanism, so a controlled trial in the subgroup is needed (Kohno et al. 2021).
- If the 30-bpm POTS threshold is a poor predictor of treatment response compared to a broader orthostatic intolerance measure (e.g., cerebral blood flow drop or COMPASS-31 autonomic symptom score), then the formal POTS diagnosis is less useful than a simpler, physiology-based frame — and the predictive value of the threshold should be tested prospectively rather than assumed.
- Individual-level falsifier: a patient who fails well-run trials of fludrocortisone (adequate dose, adequate time), midodrine (adequate dose, monitored supine BP), and rate control (ivabradine or low-dose beta-blocker, adequate time), with no improvement in any orthostatic symptom, is genuine evidence that autonomic pharmacology is not that patient’s lever — and the honest move is to stop investing in this pathway and move to the next one.
7 What you can actually do
This is not medical advice; it is a map of the conversation to have with a clinician.
- Do the simplest thing first — but do it well. Salt, water, and compression are the evidence-supported foundation. A trial of waist-high 20–30 mmHg compression stockings during upright activity, combined with 3 L of water and 3–6 g of added sodium per day (adjusted by a prescriber), is a genuine trial before any drug. If you cannot physically pull on the stockings — a real problem in moderate-to-severe ME/CFS — ask a caregiver or use a donning aid.
- Track one symptom, not everything. Pick the single orthostatic symptom that limits you most — dizziness on standing, brain fog when upright, the need to sit in the shower — and track it. A simple daily note (“stood 3 minutes before dizzy, midodrine 5 mg”) is enough. Do not build a multi-column diary if the effort triggers PEM.
- Know that a stand test is a snapshot. The 30-bpm threshold has poor day-to-day reproducibility, and a single negative test does not rule out orthostatic intolerance. If your symptoms are suggestive but the numbers do not cross the line, ask about a broader autonomic assessment (COMPASS-31 questionnaire, cerebral blood flow Doppler where available) rather than accepting a negative POTS screen as a negative dysautonomia screen (Sletten et al. 2012).
- Make each drug trial concrete and time-limited. One drug at a time, a named dose, a named reassessment point (e.g., reassess standing tolerance at 6 weeks on fludrocortisone 0.1 mg, stop if no improvement), and a stop-rule. Do not add a second drug before the first has been judged at an adequate dose and duration. If a drug helps partially, the prescriber can decide whether to add a second mechanism — but adding drugs before the first is evaluated makes it impossible to know what did what.
- Coordinate across conditions. If you also have MCAS, the antihistamines and stabilisers may affect your blood pressure and heart rate. If you also have hypermobility, compression and postural strategies may matter more than drugs. One clinician should hold the full list — and note that cimetidine (an H2 antihistamine sometimes suggested for post-infectious POTS) is a potent CYP450 inhibitor that interacts with many POTS drugs, so famotidine is the safer H2 default.
- Accept a partial win. Standing through a shower without sitting is a win. Walking to the kitchen without presyncope is a win. The energy failure may still be there — that does not mean the treatment failed. It means you addressed one amplifier in a multi-amplifier illness.
- Take a well-run failure as a finding and bring it back to the clinician — it points you away from the autonomic-pharmacology path and toward the next hypothesis. It does not mean you are not sick. It is not a verdict on your illness.
8 The bottom line
POTS treatments run from salt and compression through fludrocortisone, midodrine, ivabradine, and pyridostigmine — each targeting a different piece of the system [Pierson et al. (2025)](Freitas et al. 2000)(Kwok et al. 2026). A single failed drug tests one mechanism, not the whole dysautonomia. A sequence of well-run failures is genuine evidence that pharmacology is not your lever — and that is useful information, not a verdict on you.
For the comprehensive, fully-cited picture of how cardiovascular dysfunction and autonomic dysregulation are weighed among the many candidate mechanisms in ME/CFS, see (Loth 2026).